Please login to the form below

Not currently logged in
Email:
Password:

abiraterone

This page shows the latest abiraterone news and features for those working in and with pharma, biotech and healthcare.

MSD and AstraZeneca announce phase 3 results for prostate cancer therapy

MSD and AstraZeneca announce phase 3 results for prostate cancer therapy

MSD – known as Merck &Co in the US and Canada – and AstraZeneca have shared positive results from the PROpel phase 3 trial for the combination therapy of Lynparza (olaparib) plus abiraterone ... The data published in NEJM Evidence emphasises the

Latest news

More from news
Approximately 6 fully matching, plus 65 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    outperforming J&J's Zytiga [abiraterone].

  • Taking a strategic approach Taking a strategic approach

    But in oncology Zytiga (abiraterone) was last year not recommended for an early use indication in final draft guidance from NICE, but that appraisal process is currently on hold after Janssen

  • Pharma deals during October 2013 Pharma deals during October 2013

    AstraZeneca is focusing on developing its regional oncology portfolio as evidenced by the closure of a co-promotion deal with Janssen in Japan for Zytiga (abiraterone acetate), an innovative oral therapy

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    Janssen is developing its strengths in other areas too, and Rodriguez noted the company's recent developments in oncology, including the launch of abiraterone acetate for prostate cancer – it's “a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...
Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...